ERBB2 and neoplasm: Overexpression of other receptor tyrosine kinases, including HER2, HER3, MPM7, and coexpression of all four HER family member (HER1, HER2, HER3, HER4) receptors, also may contribute to tumor resistance to EGFR-targeting agents [26,42,43,44].